Gastrointestinal Cancer | Specialty

HCC Risk Comparable in Hepatitis C Patients Treated With DAA or Interferon

April 20th 2017

A meta-analysis found that patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.

Inherited Mutations Play Greater Role in CRC Than Previously Thought

April 20th 2017

Matthew B. Yurgelun, MD, discusses a study that determined that nearly 10% of patients with colorectal cancer had germline cancer susceptibility gene mutations and its implications for patients and their families.

After a 10-Year Lull, Trials in Liver Cancer Show Promise

April 18th 2017

A panel of experts discusses standard treatments for early-stage and advanced liver cancer, reviews investigational second-line therapies, and expresses optimism that some of these therapies may one day improve outcomes for patients.

Dr. Mariette on Takeaways from a Study of Esophageal and Gastric Cancer Surgery

April 18th 2017

Christophe Mariette, MD, PhD, surgical oncologist, professor of Surgery, University Hospital of Lille, discusses the main takeaways from a study investigating postoperative mortality after patients undergo surgery for esophageal and gastric cancer.

Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial

April 17th 2017

The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.

Dr. Wong on Risk Factors for Hepatitis B-Associated HCC

April 17th 2017

Robert Wong, MD, MS, assistant clinical professor of medicine, director of research and education, Division of Gastroenterology and Hepatology at Alameda Health System, Highland Hospital, discusses the risk factors of hepatitis B-associated hepatocellular carcinoma (HCC).

Novel Radiation Therapy Techniques Should Become Standard in Esophageal Cancer Management

April 17th 2017

Steven H. Lin, MD, PhD discusses the benefits of advanced radiation technologies, including intensity-modulated radiation therapy and proton therapy, specifically for patients with esophageal cancer.

Marshall Addresses Sidedness Issue in Colorectal Cancer

April 13th 2017

John L. Marshall, MD, discusses the results of the CALGB 80405 trial and other ongoing efforts to determine the underlying molecular basis for the sidedness issue in colorectal cancer.

Expert Discusses Differences Between Early-Onset and Traditional CRC

April 11th 2017

Manish Shah, MD, discusses ongoing efforts to understand the distinction between early-onset CRC and traditional CRC.

Nivolumab Effective in Advanced Anal Cancer

April 10th 2017

According to findings from a single-arm phase II trial, treatment with the PD-1 inhibitor nivolumab (Opdivo) resulted in an overall response rate of 24.3% in previously treated patients with squamous cell carcinoma of the anal canal.

Dr. Shah on Indications of Early-Onset CRC

April 6th 2017

Manish A. Shah, MD, director of gastrointestinal oncology, Weill Cornell Medicine/New York-Presbyterian Hospital, discusses indications of early-onset colorectal cancer (CRC).

Dr. Abou-Alfa on Trial of MEK162 in Advanced Biliary Cancer

April 3rd 2017

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the trial of MEK162 in combination with gemcitabine and cisplatin in patients with untreated advanced biliary cancer.

Dual HER2 Targeting Effective in Refractory mCRC Subset

April 2nd 2017

A dual attack on HER2 expression resulted in a 30% objective response rate in heavily pretreated patients with HER2-positive metastatic colorectal cancer.

Dr. Ramanathan on Treatment Resistance in Pancreatic Cancer

March 29th 2017

Ramesh K. Ramanathan, MD, vice chair of research in the Department of Hematology/Oncology at Mayo Clinic, discusses why pancreatic cancer is resistant to several therapies, as well as the early, preclinical promise observed with immunotherapy.

Experts Raise Awareness for Colorectal Cancer

March 25th 2017

Dr. Hemphill on Molecular Profiling for Gastric Cancer Treatment

March 18th 2017

Brian Hemphill, MD, clinical oncologist, Tennessee Oncology, discusses molecular profiling for gastric cancer treatment.

Dr. Kennedy on Importance of SIRFLOX Study in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, physician-in-chief and radiation oncologist at Sarah Cannon Research Institute, discusses the importance of the SIRFLOX trial, which explored the efficacy of selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres as treatment for patients with liver-metastatic colorectal cancer (CRC) versus standard frontline chemotherapy.

Emerging Data Could Show True Benefit of Y-90 Radioembolization in Liver-Metastatic CRC

March 17th 2017

Andrew Kennedy, MD, speaks on the various approaches used in clinical practice to treat patients who have colorectal cancer with liver metastases.

Sequencing, Patient Selection Among Challenges in GI Cancers

March 17th 2017

Brian Hemphill, MD, provides insight on some of the challenges currently being faced in gastrointestinal malignancies and how molecular profiles of tumors will dramatically change outcomes for these patients.

Dr. O'Neil on Stemness Inhibitors for CRC Treatment

March 17th 2017

Bert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of Medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the potential for stemness inhibitors as a treatment for patients with metastatic colorectal cancer (mCRC).